Inositol Hexanicotinate (Flush-Free Niacin).
Slow-release niacin. Minimal flush, minimal benefits. A niacin ester: six nicotinic acid units on an inositol core, freed slowly by esterases. It supports vitamin B3 status and NAD production without the hot skin flush.
Reviewed March 2026
- Category
- Vitamin
- Also filed under
- CholesterolCirculation
What Inositol Hexanicotinate (Flush-Free Niacin) is, and what it does.
- Does it work
- It suits people who want the nicotinic acid form without flushing. Worth knowing that human work shows the ester splits slowly and only partly.
- How much to take
- Start with 500mg a day, and 500 to 1,500mg is the daily maintenance band. Taking it with food and splitting it across the day suits most routines.
- Time to feel it
- Weeks. Because the ester lets nicotinic acid go slowly, any change lands on a blood panel over four to eight weeks rather than as something you sense.
- The first dose
- Usually uneventful, and that's the point. Little or no flush, no warmth, no tingling, while esterases quietly begin splitting the molecule apart.
- With regular use
- Four to eight weeks of daily use keeps B3 topped up through the Preiss-Handler route into NAD. What changes reads on a blood panel rather than as a sensation.
- How well tolerated
- Generally well tolerated and much gentler on flushing than plain nicotinic acid. Gram-scale niacin forms warrant a doctor's input, especially alongside a lipid medicine.
- How it feels
- Almost nothing, by design. The prickly warm flush that plain nicotinic acid brings on is largely absent here, which is why people choose this form.
- The overlooked benefit
- About 85 percent of its weight is nicotinic acid, but human work shows the ester splits slowly and partly, so the free niacin released is a fraction of that.
500 to 1,500mg a day is where Inositol Hexanicotinate (Flush-Free Niacin) works.
Source: Unfer 2017 meta (PCOS) + Levine 1995 (anxiety)
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 10 human trials with 50% consistency.
- reduced skin flushing compared with immediate-release nicotinic acidRandomised trial
- slow and partial hydrolysis to free nicotinic acidNarrative review
- blood lipid measures already in the normal rangeMeta-analysis
- NAD precursor supply through the Preiss-Handler routeNarrative review
Questions people ask about Inositol Hexanicotinate (Flush-Free Niacin).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Inositol hexanicotinate is six nicotinic acid molecules esterified to inositol, releasing free nicotinic acid slowly on hydrolysis. Combining it with plain niacin stacks the same molecule at two release rates.
Hydrolysis of the hexanicotinate ester yields nicotinic acid, the same acid that drives the flush response. Total nicotinic acid load should be counted across both ingredients rather than separately.
The molecule releases one inositol per six nicotinic acids, so it contributes to the inositol pool as well as the niacin pool. Formulas pairing the two are adding to a supply the ester already provides.
Nicotinic acid is cleared partly by N-methylation, which draws on S-adenosylmethionine and raises methyl-group demand. Betaine restores methionine from homocysteine and covers that demand.
Methyl-group turnover rises when a nicotinic acid load is methylated for clearance, and 5-methyltetrahydrofolate is the folate form that remethylates homocysteine. The pairing keeps the one-carbon cycle supplied.
Methionine synthase needs methylcobalamin to move a methyl group from folate to homocysteine. It sits in the same cycle that supplies the methyl groups used to clear nicotinic acid.
Niacin-bound chromium complexes use nicotinic acid as the ligand that carries chromium, which is why the two appear together in formulas. A hexanicotinate source contributes nicotinic acid to that same chemistry.
Nicotinic acid enters the NAD pool by the Preiss-Handler route while nicotinamide riboside enters through nicotinamide riboside kinase. Both end at the same dinucleotide, so their contributions are additive rather than distinct.
NMN feeds NAD synthesis one step from the dinucleotide, and released nicotinic acid feeds the same pool through a parallel salvage route. Counting total NAD precursor load across both is the sensible reading.
About sixty milligrams of dietary tryptophan converts to roughly one milligram of niacin equivalent through the kynurenine pathway, which is why niacin requirements are expressed in niacin equivalents. Tryptophan and any nicotinic acid source feed the same NAD pool from two directions. The conversion is inefficient and depends on riboflavin and vitamin B6 status.
Kynurenine 3-monooxygenase in the tryptophan to niacin pathway is an FAD-dependent enzyme, so riboflavin status governs how much niacin the body makes for itself. A formula supplying a nicotinic acid ester alongside riboflavin covers both the exogenous and the endogenous route. This is settled cofactor biochemistry.
Kynureninase requires pyridoxal 5-phosphate, and low B6 status diverts tryptophan away from the niacin branch of the pathway. That is why B6 status shows up in urinary kynurenine metabolites. The pairing supports the conversion route rather than the ester itself.
Nicotinic acid released from the ester enters the Preiss-Handler pathway and is converted through nicotinic acid mononucleotide and nicotinic acid adenine dinucleotide to NAD. NAD is the endpoint every niacin form is aiming at, reached by different numbers of enzymatic steps. Stating the pathway makes clear what the ester is a delivery vehicle for.
Niacinamide reaches NAD by the salvage pathway rather than the Preiss-Handler route, and it does not activate the GPR109A receptor that produces cutaneous flushing. Combining it with a nicotinic acid ester supplies the same vitamin activity by two routes into one pool. The two forms are not interchangeable for anything beyond vitamin adequacy, and the label should say which is present.
Nicotinamide riboside is phosphorylated by nicotinamide riboside kinase directly to nicotinamide mononucleotide, bypassing the steps a nicotinic acid ester must go through. Both converge on NAD. Stacking them raises total precursor load without adding a distinct mechanism.
Lecithin carries phosphatidylinositol, which is the dietary form most inositol arrives in, and the inositol backbone of this ester is myo-inositol. The two supply the same molecule in different chemical company. Once the ester is hydrolysed, its inositol joins the same pool.
Phosphatidylcholine and phosphatidylinositol are both membrane phospholipids assembled through the CDP-diacylglycerol and Kennedy pathways. Supplying inositol and choline together supports the head-group pool for both. This is membrane phospholipid biochemistry and needs no combination trial.
Choline and inositol are the two classical lipotropic head groups, each phosphorylated then activated to a CDP intermediate before joining diacylglycerol. They are routinely formulated together for that reason. The pairing is about phospholipid head-group supply, stated without any claim about liver fat.
Every kinase step in inositol phosphate cycling and in NAD synthesis uses ATP as its magnesium complex, so magnesium is a silent participant in both halves of this molecule's fate. Adequacy matters more than any additive effect. Nothing here suggests one raises the absorption of the other.
Marine omega-3 fatty acids act on hepatic triglyceride assembly and PPAR signalling, while nicotinic acid acts on adipose lipolysis and hepatic lipoprotein handling. Formulas built around supporting blood lipids already within a normal range often place them together for that non-overlap. The combination has not been isolated for the ester form specifically.
Chromium appears alongside niacin in formulas descended from the old glucose tolerance factor literature, in which the two were described as components of one complex. That description has not held up as chemistry. The pairing persists as a formulation convention and should be presented as one.
Berberine activates AMP-activated protein kinase and raises hepatic LDL receptor expression, a different lever from anything a nicotinic acid source pulls. Lipid-support formulas combine them for that reason. No trial has isolated berberine with a nicotinic acid ester.
Red yeast rice contains monacolin K, which inhibits HMG-CoA reductase, and nicotinic acid acts on lipoprotein handling elsewhere in the same system. Both also carry monitoring considerations around muscle and liver markers, and those considerations add rather than cancel. Anyone combining them should be doing so with clinical oversight.
Nothing specific on file for Inositol Hexanicotinate (Flush-Free Niacin). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Inositol Hexanicotinate (Flush-Free Niacin) actually does.
Inositol hexanicotinate is a hexaester: six nicotinic acid molecules bonded through ester linkages to the six hydroxyl groups of one myo-inositol molecule, giving a molecule that is roughly 85 percent nicotinic acid by weight.
The ester bonds must be hydrolysed by serum and tissue esterases before free nicotinic acid is released, which is the whole reason its release profile differs from an immediate-release nicotinic acid tablet.
Nicotinic acid produces cutaneous flushing by activating the GPR109A receptor on Langerhans cells, driving prostaglandin D2 and E2 release and skin vessel dilation; a form that keeps peak free nicotinic acid low produces less of that response.
Free nicotinic acid is converted to NAD through the Preiss-Handler pathway, sequentially by nicotinate phosphoribosyltransferase, NMN adenylyltransferase and NAD synthetase.
Where Inositol Hexanicotinate (Flush-Free Niacin) comes from.
This one is built in a reactor, not extracted from anything. Chemists take inositol, which comes from corn or rice by-products or from a fermentation tank, and attach six niacin molecules to it. The finished powder is washed and crystallised, and how much loose niacin is left over is the number that decides how the material behaves.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Myo-inositol is produced either by acid hydrolysis of phytate recovered from corn steep liquor and rice bran, or by microbial fermentation from glucose. Nicotinic acid is manufactured industrially by oxidation or ammoxidation of alkylpyridines such as 3-picoline or 2-methyl-5-ethylpyridine.
Nicotinic acid is activated, commonly as nicotinoyl chloride, and reacted with myo-inositol in the presence of a base to esterify all six hydroxyl groups. Reaction time, temperature and molar excess determine how completely the sixth position is reached.
The crude ester is precipitated, washed to remove residual acid, chloride and unreacted nicotinic acid, and recrystallised. Removing free nicotinic acid is the step that determines the flushing profile of the finished material.
Grades are specified on assay of the hexaester, on residual free nicotinic acid, on residual solvent and on heavy metals. Free nicotinic acid is the specification that most distinguishes one supplier's material from another's.
Milled to a defined particle size and either packed as neat powder or granulated with a binder for tablet compression.
Getting Inositol Hexanicotinate (Flush-Free Niacin) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.